Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1 | Ophthalmology Times
(Image Credit: AdobeStock/doucefleur) Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt disease type 1 (STGD1). According to the company, this marks the first successful pivotal trial in patients with the…
Kiora Pharmaceuticals receives patent for additional and novel formulations of KIO-100 compounds | Ophthalmology Times
(Image Credit: AdobeStock/ronstik) The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of the KIO-100 family of compounds from Kiora Pharmaceuticals. In July 2025, the company announced it had…
Collarettes common but largely stable in moderate-to-severe dry eye patients | Ophthalmology Times
(Image Credit: AdobeStock/Alessandro Grandini) In utilizing the Dry Eye Assessment and Management (DREAM) study data, a team of researchers found that lid margin collarettes were common in patients with moderate-to-severe dry eye disease (DED), but a majority of those patients’…
Clinical Experience and Integration of New Dry Eye Disease Therapies in the Clinic | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Managing Unique Dry Eye Disease Subtypes in Patients | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081 | Ophthalmology Times
(Image Credit: AdobeStock/Who is Danny) AAVantgarde and AGC Biologics have entered into an agreement in which AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgarde’s dual-vector gene therapies for inherited retinal disorders, AAVB-039 and AAVB-081.1 Most recently, AAVantgarde Bio…
AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives | Ophthalmology Times
(Image Credit: AdobeStock/Julien Tromeur) Editor’s Note: This content was generated with the assistance of AI. At AAO 2025, the conversation around retinal disease treatment moved decisively toward the future—one defined by senolytic agents, next-generation gene and optogenetic therapies, disease-modifying approaches…
Ocular Therapeutix randomizes first patient in HELIOS-3 | Ophthalmology Times
(Image Credit: AdobeStock/ronstik) Ocular Therapeutix has randomized the first patient in its HELIOS-3 phase 3 registrational program for AXPAXLI (or OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR). The company describes AXPAXLI as an investigational, bioresorbable, intravitreal hydrogel incorporating…
AAO 2025 Takeaways: How imaging and remote monitoring are transforming retinal care | Ophthalmology Times
(Image Credit: AdobeStock/Mohwet) Editor’s Note: This content was generated with the assistance of AI. AAO 2025 showcased some of the most significant leaps in retinal imaging and disease surveillance the field has seen in over a decade. Three presentations—delivered by…
Regeneron’s EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO | Ophthalmology Times
The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals for the treatment of patients with macular edema following retinal vein occlusion (RVO) with up to every 8-week dosing after an initial monthly…